Medigen Vaccine Biologics Stock Total Debt
| 6547 Stock | TWD 38.90 0.25 0.64% |
Medigen Vaccine Biologics fundamentals help investors to digest information that contributes to Medigen Vaccine's financial success or failures. It also enables traders to predict the movement of Medigen Stock. The fundamental analysis module provides a way to measure Medigen Vaccine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigen Vaccine stock.
Medigen |
Medigen Vaccine Biologics Company Total Debt Analysis
Medigen Vaccine's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Medigen Vaccine Total Debt | 286.54 M |
Most of Medigen Vaccine's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigen Vaccine Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Medigen Vaccine Biologics has a Total Debt of 286.54 M. This is 89.58% lower than that of the Healthcare sector and 11.78% lower than that of the Biotechnology industry. The total debt for all Taiwan stocks is 94.61% higher than that of the company.
Medigen Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigen Vaccine's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medigen Vaccine could also be used in its relative valuation, which is a method of valuing Medigen Vaccine by comparing valuation metrics of similar companies.Medigen Vaccine is currently under evaluation in total debt category among its peers.
Medigen Fundamentals
| Return On Equity | 0.0662 | |||
| Return On Asset | 0.0209 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 24.78 B | |||
| Shares Outstanding | 327.2 M | |||
| Shares Owned By Insiders | 27.99 % | |||
| Shares Owned By Institutions | 5.13 % | |||
| Price To Earning | 34.63 X | |||
| Price To Book | 4.71 X | |||
| Price To Sales | 10.51 X | |||
| Revenue | 3.28 B | |||
| Gross Profit | 2.31 B | |||
| EBITDA | 1.53 B | |||
| Net Income | 1.41 B | |||
| Cash And Equivalents | 2.12 B | |||
| Cash Per Share | 9.95 X | |||
| Total Debt | 286.54 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 9.72 X | |||
| Book Value Per Share | 17.52 X | |||
| Cash Flow From Operations | 579.89 M | |||
| Earnings Per Share | 0.91 X | |||
| Number Of Employees | 16 | |||
| Beta | 0.89 | |||
| Market Capitalization | 23.36 B | |||
| Total Asset | 5.3 B | |||
| Z Score | 48.6 | |||
| Net Asset | 5.3 B |
About Medigen Vaccine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigen Vaccine Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigen Vaccine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigen Vaccine Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medigen Vaccine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medigen Vaccine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Vaccine will appreciate offsetting losses from the drop in the long position's value.Moving together with Medigen Stock
Moving against Medigen Stock
| 0.93 | 2891 | CTBC Financial Holding | PairCorr |
| 0.88 | 2891B | CTBC Financial Holding | PairCorr |
| 0.83 | 2883 | China Development | PairCorr |
| 0.77 | 4162 | PharmaEngine | PairCorr |
| 0.74 | 2330 | Taiwan Semiconductor | PairCorr |
The ability to find closely correlated positions to Medigen Vaccine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medigen Vaccine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medigen Vaccine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medigen Vaccine Biologics to buy it.
The correlation of Medigen Vaccine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medigen Vaccine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medigen Vaccine Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medigen Vaccine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medigen Stock Analysis
When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.